Evidence map›Paper›PMID 39789153›Full record

Trial reportBritish journal of cancer2025

Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study.

Joe M O'Sullivan, Daniel Heinrich, Elena Castro, Saby George, Sabina Dizdarevic, Sergio Baldari, Markus Essler, Igle Jan de Jong, Secondo Lastoria, Peter G Hammerer and 5 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02141438 (Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02141438 completednot on this map

Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

TypeobservationalSponsorBayerRan2014 to 2024Enrolled1,472ConditionsMetastatic Castration-resistant Prostate CancerArmsRadium-223 dichloride (Xofigo, BAY88-8223)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Joe M O'SullivanPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast and Northern Ireland Cancer Centre, Belfast, UK. joe.osullivan@qub.ac.uk.ORCID http://orcid.org/0000-0001-6999-2739
Daniel HeinrichDepartment of Medical and Radiation Oncology, Innlandet Hospital Trust, Gjøvik, Norway.
Elena CastroHospital Universitario 12 de Octubre, Madrid, Spain.
Saby GeorgeRoswell Park Cancer Institute, Buffalo, NY, USA.
Sabina DizdarevicUniversity Hospitals Sussex NHS Foundation Trust, Clinical Imaging Science Centre, Brighton & Sussex Medical School, University of Sussex and Brighton, Brighton, UK.
Sergio BaldariNuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.
Markus EsslerDepartment of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
Igle Jan de JongDepartment of Urology, University Medical Center Groningen, Groningen, The Netherlands.
Secondo LastoriaIRCCS National Cancer Institute, Fondazione Senatore G. Pascale, Naples, Italy.
Peter G HammererDepartment of Urology, Academic Hospital, Braunschweig, Germany.
Bertrand TombalCliniques Universitaires Saint Luc, Brussels, Belgium.
Nicholas D JamesThe Institute of Cancer Research, London, UK.
Jeff MeltzerBayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
Per SandströmBayer A/S, Copenhagen, Denmark.
Oliver SartorMayo Clinic, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlkaline phosphatase (ALP) declines and pain responses can occur during radium-223 (

methodsFor patients with metastatic castration-resistant prostate cancer treated with

resultsOf 785 patients with baseline and Week 12 ALP measurements, 779 were eligible for the OS analyses. Overall, 80% of patients had an ALP decline. Median OS was longer in patients with than without an ALP decline (18.1 versus 14.2 months; HR 0.74; 95% CI 0.60-0.92). In patients with an ALP decline, there was no clear OS difference between those with versus without a pain response. For patients without ALP decline, median OS was longer in those with versus without a pain response (16.2 versus 10.9 months; HR 0.50; 95% CI 0.32-0.77).

conclusionsDecreases in ALP and/or pain during CLINICAL

trial registrationClinicalTrials.gov identifier NCT02141438. Analyses from the radium-223 REASSURE global study suggest that declines in alkaline phosphatase and pain during treatment may predict longer survival in patients with advanced prostate cancer and may help doctors make decisions with their patients.

Indexed as

Alkaline PhosphataseCancer PainPainProstatic Neoplasms, Castration-ResistantRadiumAgedAged, 80 and overBone NeoplasmsHumansMaleMiddle AgedPain MeasurementTreatment OutcomeAlkaline PhosphataseRadiumRadium-223

Identifiers

PMID39789153
PMCPMC11833053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.